Irinotecan Hydrochloride + Rifapentine Interaction
Majorinteraction on record
Description
Strong CYP3A4 inducer substantially reduces exposure to irinotecan and its active metabolite SN-38. Avoid use or substitute non-enzyme inducing therapies at least 2 weeks prior to initiation.
Mechanism
CYP3A4 enzyme induction
Source: NLP:irinotecan hydrochloride